Basilea Secures $30 Million in Funding from BARDA to Advance Novel Antifungal Treatment

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, has announced that it has received $30 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the advancement of its novel antifungal treatment, fosmanogepix. This funding is part of an existing agreement between Basilea and BARDA, which aims to develop innovative treatments for severe bacterial and fungal infections.

The funding will be used to continue the phase 3 development of fosmanogepix, a first-in-class broad-spectrum antifungal that has shown promising results in treating invasive fungal infections, including aspergillosis and candidiasis. Fosmanogepix has a novel mechanism of action and has demonstrated activity against common species of Candida and Aspergillus, including multi-drug-resistant strains such as Candida auris and Candida glabrata.

The BARDA funding is a significant milestone for Basilea, as it demonstrates the authority's confidence in the company's ability to develop innovative treatments for infectious diseases. The funding is part of a larger agreement between Basilea and BARDA, which could provide up to $268 million in non-dilutive funding over 12 years, if all options are exercised. This agreement highlights the importance of public-private partnerships in driving the development of new treatments for infectious diseases.

Invasive fungal infections are a significant public health concern, particularly among immunocompromised patients such as those with hematologic malignancies, transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality, and there is a significant need for new and effective treatments. Fosmanogepix has the potential to address this unmet medical need, and the continued support from BARDA will enable Basilea to accelerate the development of this promising treatment.

Basilea's CEO, David Veitch, expressed his gratitude for the continued support from BARDA, stating that the funding will enable the company to advance the clinical development of fosmanogepix and bring this innovative treatment to patients who need it most. The company's commitment to developing novel treatments for infectious diseases is evident in its pipeline, which includes several promising candidates, including BAL2062, a first-in-class antifungal derived from a natural product.

The development of fosmanogepix and other innovative treatments for infectious diseases is critical to addressing the growing threat of antimicrobial resistance. The World Health Organization (WHO) has identified antimicrobial resistance as one of the biggest threats to global health, and the development of new treatments is essential to combating this threat. Basilea's work in this area is a testament to the company's commitment to improving public health and its dedication to developing innovative treatments that address significant unmet medical needs.

In conclusion, the $30 million in funding from BARDA is a significant milestone for Basilea and underscores the company's commitment to developing innovative treatments for infectious diseases. The continued support from BARDA will enable Basilea to accelerate the development of fosmanogepix and bring this promising treatment to patients who need it most. As the threat of antimicrobial resistance continues to grow, the development of new treatments such as fosmanogepix is critical to addressing this public health concern.